Loading
A phase 2 trial of Nivolumab in ovarian cancer, run by USWM CT, LLC, active and no longer recruiting.
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) is a phase 2 interventional study registered as NCT05601752 by USWM CT, LLC, with 66 participants planned, started 2023-06-26 and due to reach its primary completion in 2026-08-12. Interventions recorded: Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/